Search Results - "Schockaert, Jana"

Preclinical immunogenicity risk assessment of biotherapeutics using CD4 T cell assays by Walsh, Robin E, Nix, Angela, Ackaert, Chloé, Mazy, Aurélie, Schockaert, Jana, Pattyn, Sofie, Malherbe, Laurent

“…T-cell dependent antibody responses to biotherapeutics remain a challenge to the optimal clinical application of biotherapeutics because of their capacity to…”
Get full text

Immunopeptidomic Data Integration to Artificial Neural Networks Enhances Protein-Drug Immunogenicity Prediction by Barra, Carolina, Ackaert, Chloe, Reynisson, Birkir, Schockaert, Jana, Jessen, Leon Eyrich, Watson, Mark, Jang, Anne, Comtois-Marotte, Simon, Goulet, Jean-Philippe, Pattijn, Sofie, Paramithiotis, Eustache, Nielsen, Morten

“…Recombinant DNA technology has, in the last decades, contributed to a vast expansion of the use of protein drugs as pharmaceutical agents. However, such…”
Get full text

A Peptide Vaccine Candidate Tailored to Individuals' Genetics Mimics the Multi-Targeted T Cell Immunity of COVID-19 Convalescent Subjects by Somogyi, Eszter, Csiszovszki, Zsolt, Molnár, Levente, Lőrincz, Orsolya, Tóth, József, Pattijn, Sofie, Schockaert, Jana, Mazy, Aurélie, Miklós, István, Pántya, Katalin, Páles, Péter, Tőke, Enikő R.

“…Long-term immunity to coronaviruses likely stems from T cell activity. We present here a novel approach for the selection of immunoprevalent SARS-CoV-2-derived…”
Get full text

Abstract 701: Immunogenicity risk assessment and mitigation tools by Osmani, Amin, Pattijn, Sofie, Schockaert, Jana, Mazy, Aurélie, Ackaert, Chloé

“…Abstract New immuno-oncology mAbs or agents with other structures have revolutionized treatment options for several malignancies in the past few years, and…”
Get full text

Abstract 4992: In vitro exhausted T cell assay for immuno-oncology candidates by Osmani, Amin, Lamy, Juliette, Janss, Thibaut, Giltaire, Séverine, Pattijn, Sofie, Schockaert, Jana

“…Abstract The need to better understand the tumour microenvironment (TME) dictates the characterization of the cell types involved, the roles they play and how…”
Get full text

Abstract 414: Suppressive bioassays using macrophages and MDSCs by Osmani, Amin, Janss, Thibaut, Jonckheere, Thibault, Giltaire, Séverine, Pattijn, Sofie, Schockaert, Jana

“…Abstract The increasing interest in the tumour microenvironment leads to focus on new bioassays to represent all the players of the cancer immune response…”
Get full text

Immunogenicity Risk Assessment of Process-Related Impurities in An Engineered T Cell Receptor Cellular Product by Mora, Johanna, Forman, Daron, Hu, Jennifer, Ijantkar, Akshata, Gokemeijer, Jochem, Kolaja, Kyle L, Picarillo, Caryn, Jawa, Vibha, Yue, Hai, Lamy, Juliette, Denies, Sofie, Schockaert, Jana, Ackaert, Chloé

“…Cell therapies such as genetically modified T cells have emerged as a promising and viable treatment for hematologic cancers and are being aggressively pursued…”
Get more information

Abstract 5662: Early unwanted immunogenicity assessment of immuno oncology drugs by Pattyn, Sofie, Vlaming, Martijn, Pieters, Alanah, Schockaert, Jana

“…Abstract Bispecifics targeting multiple antigens or epitopes have been showing great promise for treatment of cancer. However, managing unwanted immunogenicity…”
Get full text

Ex vivo comparative immunogenicity assessment (EVCIA) to determine relative immunogenicity in chronic plaque psoriasis in participants receiving Humira® or undergoing repeated switches between Humira® and AVT02 by Richter, Kathleen, Haliduola, Halimu N, Schockaert, Jana, Mazy, Aurélie, Reznichenko, Nataliya, Guenzi, Eric, Berti, Fausto

“…Summary Immunogenicity against biologic medicines is ubiquitous, and it is traditionally measured by the final humoral response. However, the onset of a…”
Get full text

Abstract 3288: The use of in vitro assays to assess and measure gene therapy immunogenicity by Schockaert, Jana, Janss, Thibaut J., Lamy, Juliette, Mazy, Aurélie, Boelen, Ellen, Lefevre, Simon, Pattijn, Sofie

“…Abstract Introducing the gene therapy product into human cells requires a vector that will deliver the gene into the cells and incorporate those genes into the…”
Get full text

The mutational landscape of SARS-CoV-2 variants diversifies T cell targets in an HLA-supertype-dependent manner by Hamelin, David J, Fournelle, Dominique, Grenier, Jean-Christophe, Schockaert, Jana, Kovalchik, Kevin A, Kubiniok, Peter, Mostefai, Fatima, Duquette, Jérôme D, Saab, Frederic, Sirois, Isabelle, Smith, Martin A, Pattijn, Sofie, Soudeyns, Hugo, Decaluwe, Hélène, Hussin, Julie, Caron, Etienne

“…The rapid, global dispersion of SARS-CoV-2 has led to the emergence of a diverse range of variants. Here, we describe how the mutational landscape of…”
Get more information